100% Quality Guarantee
PhD-Level Technical Support
Anti-CD138 indatuximab ravtansine biosimilar mAb HDBS0014
Key Features

Indatuximab Biosimilar (CD138) Antibody (HDBS0014)

SKU HDBS0014
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein CD138
Reactivity Human
Host Species Chimeric Humanized
Isotype IgG4
$569

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Indatuximab Biosimilar (CD138) Antibody (HDBS0014)

The CD138 Indatuximab Ravtansine Biosimilar (MAB-HDBS0014) is a highly specific monoclonal antibody designed for research involving CD138, a cell surface glycoprotein commonly expressed in plasma cells. This biosimilar antibody, derived from the innovative antibody-drug conjugate (ADC) platform, targets and delivers the cytotoxic agent ravtansine specifically to CD138-expressing cells, leading to targeted cell death.CD138, also known as syndecan-1, is a well-established marker for plasma cells and plays a crucial role in cell adhesion and migration. Its overexpression is frequently observed in multiple myeloma, a type of blood cancer that originates in plasma cells.

By targeting CD138 with the potent cytotoxic payload ravtansine, this biosimilar antibody offers a promising approach for the treatment of multiple myeloma and potentially other CD138-expressing malignancies.The Anti-CD138 Indatuximab Ravtansine Biosimilar (MAB-HDBS0014) opens up new possibilities for targeted therapy and personalized medicine in the field of oncology. Its high specificity and efficacy make it a valuable tool for studying CD138 biology, developing novel treatment strategies, and advancing precision medicine approaches for cancer patients.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose